



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,201	04/07/2006	Bjarne Due Larsen	50412/015002	5189
21559	7590	04/07/2010	EXAMINER	
CLARK & ELBING LLP			AUDET, MAURY A	
101 FEDERAL STREET				
BOSTON, MA 02110			ART UNIT	PAPER NUMBER
			1654	
		NOTIFICATION DATE	DELIVERY MODE	
		04/07/2010	ELECTRONIC	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/534,201	LARSEN ET AL.	
	Examiner MAURY AUDET	Art Unit 1654	
All Participants:	Status of Application: <u>Pending</u>		
(1) MAURY AUDET, Examiner.	(3) _____.		
(2) Jeff Kessler, Applicant's Representative.	(4) _____.		
Date of Interview: <u>26 March 2010</u>	Time: <u>1030</u>		
Type of Interview:	<input checked="" type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)		
Exhibit Shown or Demonstrated: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	If Yes, provide a brief description: _____		
Part I.			
Rejection(s) discussed: NA			
Claims discussed: All			
Prior art documents discussed: NA			
Part II.			
SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:			
<p>The Examiner telephoned Applicant because the amended claims are unsearchable. The 4th bond of one of the carbonyl groups in each of the 2 subgenuses now claimed is empty. The claims are indefinite as to what molecule is to be attached here. Leaving all the species claimed in dependent claims arguably now lacking antecedent basis. The Examiner indicated either a Final Rejection necessitated by amendment or a Form 90 communication could be sent, the latter giving a 1-month response period in which to correct this flaw. Applicant requested the 2nd option and indicated it was felt this was supposed to be H group (e.g. H2) and that amendment thereto to distinctly claim the invention would be carried out.</p>			
Additionally two other points were discussed:			
<ol style="list-style-type: none"> 1. Applicant agreed to positively amend by Markush group what is meant at position Rx as a "hydrophobic group", which is described in the specification, so that reasonable search of the art may be conducted on these subgenus, since a hydrophobic group leaves open an extremely broad class of molecules that could be attached here (art thereto; rendering an undue search burden). 2. Applicant indicated they will identify which species compounds of the 2 subgenus were tested (e.g. Table, Figure) and found to treat arrhythmias (claim 85) to put on record a representative number of species capable of carrying out the method of use. 			
Part III.			
<input type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance			
<hr/> /Maury Audet/ Primary Examiner, Art Unit 1654			
(Applicant/Applicant's Representative Signature – if appropriate)			